| Literature DB >> 34566545 |
Qudsia Yousafi1, Humaira Amin2, Shabana Bibi3, Rafea Rafi1, Muhammad S Khan1, Hamza Ali1, Ashir Masroor4.
Abstract
Klebsiella oxytoca is a gram-negative bacterium. It is opportunistic in nature and causes hospital acquired infections. Subtractive proteomics and reverse vaccinology approaches were employed to screen out the best proteins for vaccine designing. Whole proteome of K. oxytoca strain ATCC 8724, consisting of 5483 proteins, was used for designing the vaccine. Total 1670 cytotoxic T lymphocyte (CTL) epitope were predicted through NetCTL while 1270 helper T lymphocyte (HTL) epitopes were predicted through IEDB server. The epitopes were screened for non-toxicity, allergenicity, antigenicity and water solubility. After epitope screening 300 CTL and 250 HTL epitopes were submitted to IFN-γ epitope server to predict their Interferon-γ induction response. The selected IFN-γ positive epitopes were tested for their binding affinity with MHCI-DRB1 by MHCPred. The 15 CTL and 13 HTL epitopes were joined by linkers AAY and GPGPG respectively in vaccine construct. Chain C of Pam3CSK4 (PDB ID; 2Z7X) was linked to the vaccine construct as an adjuvant. A 450aa long vaccine construct was submitted to I-TASSER server for 3D structure prediction. Thirteen Linear B cells were predicted by ABCPred server and 10 sets of discontinues epitopes for 3D vaccine structure were predicted by DiscoTope server. The modeled 3D vaccine construct was docked with human Toll-like receptor 2 (PDB ID: 6NIG) by PatchDock. The docked complexes were refined by FireDock. The selected docked complex showed five hydrogen bonds and one salt bridge. The vaccine sequence was reverse transcribed to get nucleotide sequence for In silico cloning. The reverse transcribed sequence strand was cloned in pET28a(+) expression vector. A clone containing 6586 bp was constructed including the 450 bp of query gene sequence.Entities:
Keywords: Disulfide engineering; Human TLR2; Linear B cells epitopes; Thermostability curve; pET28a (+)
Year: 2021 PMID: 34566545 PMCID: PMC8452133 DOI: 10.1007/s10989-021-10283-z
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Fig. 1Subtractive proteomic schema for vaccine construction against Klebsiella oxytoca
HTL epitopes selected for vaccine construct against Klebsiella oxytoca
| Protein ID | Alleles | Start | End | Method | Peptide sequence | Percentile rank | Adjusted rank | Allergenicity score | Antigenicity | IFN epitope score |
|---|---|---|---|---|---|---|---|---|---|---|
| A0A0H3HBY6 | HLA-DRB5*01:01 | 3 | 17 | Consensus (smm/nn/sturniolo) | EKKVVMRIRALHKRF | 0.21 | 0.21 | − 0.4281 | 0.57 | 0.030451 |
| HLA-DRB5*01:01 | 6 | 20 | Consensus (smm/nn/sturniolo) | VVMRIRALHKRFGAQ | 0.58 | 0.58 | − 0.598 | 1.24 | 0.013655 | |
| HLA-DRB5*01:01 | 2 | 16 | Consensus (smm/nn/sturniolo) | SEKKVVMRIRALHKR | 0.21 | 0.21 | − 0.5404 | 0.46 | 0.188259 | |
| A0A0H3HCH0 | HLA-DRB3*02:02 | 142 | 156 | NetMHCIIpan | QQRVAIARALAMKPS | 3.6 | 3.6 | − 4.5988 | 0.73 | 0.336966 |
| A0A0H3HAB9 | HLA-DRB3*01:01 | 117 | 131 | Consensus (comb.lib./smm/nn) | HVKGMKRDEAKAIAM | 0.71 | 0.71 | − 0.5438 | 2.1 | 0.206067 |
| HLA-DRB3*01:01 | 115 | 129 | Consensus (comb.lib./smm/nn) | LLHVKGMKRDEAKAI | 0.72 | 0.72 | − 0.4656 | 0.75 | 0.055908 | |
| HLA-DRB3*01:01 | 118 | 132 | Consensus (comb.lib./smm/nn) | VKGMKRDEAKAIAMQ | 0.72 | 0.72 | − 0.5340 | 0.49 | 0.170946 | |
| HLA-DRB3*01:01 | 116 | 130 | Consensus (comb.lib./smm/nn) | LHVKGMKRDEAKAIA | 0.74 | 0.74 | − 0.5529 | 0.63 | 0.105924 | |
| A0A0H3HGA0 | HLA-DRB5*01:01 | 85 | 99 | Consensus (smm/nn/sturniolo) | TVSRFMLLRPGTHKR | 0.88 | 0.88 | − 0.7711 | 0.42 | 0.602909 |
| HLA-DRB1*03:01 | 15 | 29 | Consensus (smm/nn/sturniolo) | GQRRVLSDISLTLKP | 1.1 | 1.1 | − 9.901 | 0.53 | 0.3684091 | |
| A0A0H3HDE1 | HLA-DRB1*03:01 | 151 | 165 | Consensus (smm/nn/sturniolo) | HGWSAVNVDDRWLFR | 0.24 | 0.24 | − 0.5072 | 0.58 | 0.937815 |
| A0A0H3H729 | HLA-DRB5*01:01 | 214 | 228 | Consensus (smm/nn/sturniolo) | RSVTRAFNHMAAGVK | 0.16 | 0.16 | − 0.697 | 1.43 | 0.509832 |
CTL epitopes selected for vaccine construct against Klebsiella oxytoca
| Cellular location | Protein ID | Peptide sequence | VaxiJen score | IFN epitope score | Water solubility | MHCPred | AllerTOP v. 2.0 | ToxinPred |
|---|---|---|---|---|---|---|---|---|
| Periplasmic | A0A0H3HK70 | TYDKLAKKY | 0.5864 | 0.045 | Good | 1.53 | ||
| A0A0H3H8B0 | MQEQRASAY | 0.5668 | 0.213 | Good | 6.32 | Non-allergenic | Non toxic | |
| A0A0H3HFM6 | LAEGLRADY | 0.4985 | 0.378 | Good | 13.40 | Non-allergenic | Non toxic | |
| A0A0H3HAJ2 | QSDAEKSGV | 1.6633 | 0.486 | Good | 18.49 | Non-allergenic | Non toxic | |
| Outer membrane | A0A0H3H611 | DSSSSDSVY | 1.4043 | 0.521 | Good | 19.19 | Non-allergenic | Non toxic |
| SSNHSADIY | 0.7153 | 0.085 | Good | 23.99 | Non-allergenic | Non toxic | ||
| FSDIDLSDV | 0.5651 | 0.089 | Good | 3.33 | Non-allergenic | Non toxic | ||
| A0A0H3H6X7 | NSDDTSYAR | 0.9284 | 0.211 | Good | 5.30 | Non-allergenic | Non toxic | |
| A0A0H3H9M6 | RTDSRQLDS | 2.1329 | 0.006 | Good | 6.17 | Non-allergenic | Non toxic | |
| Extracellular | A0A0H3H7X1 | SEEPITFEY | 0.6935 | 0.416 | Good | 15.63 | Non-allergenic | Non toxic |
| A0A0H3HDA8 | HLEQIELRY | 1.8453 | 0.191 | Good | 6.95 | Non-allergenic | Non toxic | |
| Cytoplasmic membrane | A0A0H3HF34 | QSDEVAAAA | 0.9697 | 0.348 | Good | 5.40 | Non-allergenic | Non toxic |
| A0A0H3HFF1 | HIELRALSY | 1.5293 | 0.667 | Good | 0.89 | Non-allergenic | Non toxic | |
| SADSASALM | 0.5090 | 0.977 | Good | 7.80 | Non-allergenic | Non toxic | ||
| A0A0H3HCS4 | ATSRARQPY | 0.4767 | 0.059 | Good | 41.78 | Non-allergenic | Non toxic |
Fig. 2Amino acid sequence of vaccine construct for Klebsiella oxytoca
Fig. 3Thermostability curve of Klebsiella oxytoca vaccine protein
Fig. 4Predicted 3D structure of Klebsiella oxytoca vaccine construct
Predicted B cell linear epitopes in vaccine construct for Klebsiella oxytoca
| Rank | Sequence | Start position | Score |
|---|---|---|---|
| 1 | GPGGQRRVLSDISLTL | 393 | 0.93 |
| 2 | RALAMKPSGPGPGLSW | 243 | 0.92 |
| 3 | SRQGPGPGTHDLQLAK | 348 | 0.91 |
| 3 | SDSRYAAYTVDALNSE | 162 | 0.91 |
| 3 | YGMAHKADVYAAYETT | 145 | 0.91 |
| 4 | YHLETLELRYAAYKTN | 73 | 0.89 |
| 5 | PGPGMHNSVMRLTISN | 292 | 0.88 |
| 5 | PGPGEKKVVMRIRALH | 192 | 0.88 |
| 6 | PGPGPGHGWSAVNVDD | 410 | 0.87 |
| 7 | QGVETDLPQLRALDGP | 277 | 0.86 |
| 7 | QAVSYGPGPGEKKVVM | 186 | 0.86 |
| 8 | GTHKRGPGPGGQRRVL | 386 | 0.85 |
| 8 | VVMRIRALHKRFGAGP | 217 | 0.85 |
Predicted discontinuous epitopes in 3D structure of vaccine construct for Klebsiella oxytoca
| Nos | Residues | Contact numbers | DiscoTope score |
|---|---|---|---|
| 1 | GLU123, GLU130, GLY238 | 0 | − 1.906, − 3.442, − 0.980 |
| 2 | SER66, HIS67, THR329, SER66, | 1 | 1.392, 0.663, − 2.111, 0.667 |
| 3 | GLY65, ARG70, ASN124, ASN176, VAL330, ARG70, ASN124 | 3 | 1.621, − 1.187, − 2.030, − 3.616, − 3.040, − 1.044, − 1.73 |
| 4 | LEU69, GLU173 VAL330 | 4 | − 2.100, − 2.387, − 3.220 |
| 5 | GLU71, TYR121, PRO236 | 5 | − 1.514, − 3.301, 0.379 |
| 6 | GLY65, GLU173 | 6 | 1.094, − 3.147 |
| 7 | LYS72, GLU180, THR219, LYS285 | 7 | − 3.456, − 3.119, − 0.831, − 3.436 |
| 8 | MET68, | 8 | − 0.689 |
| 9 | SER73, GLU183, MET68, LYS285 | 9 | − 2.647, − 2.797, − 1.266, − 3.673 |
| 10 | ALA127, ASN217 | 10 | − 2.900, − 1.729 |
Mutated amino acids pairs in vaccine construct of Klebsiella oxytoca
| Amino acid | Bond | |||||
|---|---|---|---|---|---|---|
| Seq# | AA | Seq# | AA | χ3 | Energy (kcal/mol) | Sum B-factors |
| 184 | Val | 218 | Val | − 86.21 | 0.07 | 10.42 |
| 156 | Ala | 163 | Asp | − 83.27 | 0.72 | 12.78 |
| 420 | Ala | 424 | Asp | 94.41 | 0.99 | 14.29 |
| 43 | Asp | 264 | Leu | 96.71 | 1.07 | 11.12 |
| 179 | Ala | 221 | Ile | − 76.81 | 1.07 | 11.90 |
Fig. 5Disulfide engineered structure of Klebsiella oxytoca vaccine construct
Fig. 6Amino acid sequence of Klebsiella oxytoca vaccine construct with cysteine mutations
Fig. 7Thermostability curve of Klebsiella oxytoca vaccine protein after disulfide engineering
Fig. 8Chain A of human toll like receptor 2 (PDB ID: 6NIG)
Fig. 9Two dimensional interactions in docked complex of human TLR2 and Klebsiella oxytoca vaccine construct
Fig. 10Three dimensional structure of docked complex of human TLR2 and Klebsiella oxytoca vaccine construct (vaccine construct: purple and solid, HTLR2: green)
Fig. 11The engineered Klebsiella oxytoca vaccine construct map for cloning
Fig. 12The cloned pET28a (+) vector showing Klebsiella oxytoca vaccine construct as red region